The FDA has approved Novo Nordisk's Wego HD, a new higher dose of semaglutide 7.2 mg given once weekly by injection.[1][4][5] The approval is based on the results of the STEP UP program of studies, including the 72-week STEP UP study of 1,407 adult patients with obesity (BMI ≥ 30 kg/m²) without diabetes.[1][4] In this study, Wego's HD achieved an average weight loss of 20.7%, with approximately one-third of participants losing 25% or more.[1][4] The previous highest dose of Wego was 2.4 mg, which is approved for weight reduction and reducing the risk of cardiovascular events.[1][5] Wego's HD is used in conjunction with reduced caloric intake and increased physical activity in patients who have tolerated the 2.4 mg dose for at least 4 weeks and need further weight reduction.[1] Novo Nordisk plans to launch Wego's HD in the US in April 2026 in a disposable pen.[4][5] This approval expands Wego's clinical profile, which includes multiple formulations and indications unavailable for other GLP-1 weight loss drugs.[1]